Item type: | Article | ||||
---|---|---|---|---|---|
Journal or Publication Title: | Annals of Anatomy - Anatomischer Anzeiger | ||||
Publisher: | ELSEVIER GMBH | ||||
Place of Publication: | MUNICH | ||||
Volume: | 232 | ||||
Page Range: | p. 151585 | ||||
Date: | 2020 | ||||
Institutions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie Medicine > Lehrstuhl für Zahnerhaltung und Parodontologie | ||||
Identification Number: |
| ||||
Keywords: | ROOT RESORPTION; ALVEOLAR BONE; CLINICAL-PHARMACOLOGY; ACETYLSALICYLIC-ACID; PHYSICAL-PROPERTIES; HPDL CELLS; FLURBIPROFEN; ASSOCIATION; INHIBITION; EXPRESSION; Orthodontic tooth movement; NSAID; Etoricoxib; mu CT; Osteoclastogenesis; Root resorption | ||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
Status: | Published | ||||
Refereed: | Yes, this version has been refereed | ||||
Created at the University of Regensburg: | Yes | ||||
Item ID: | 49563 |
Abstract
Objectives: The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe. At clinically relevant doses it has been reported to only have marginal effects on the velocity of orthodontic tooth movement (OTM). Its effects on associated ...
Abstract
Objectives: The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe. At clinically relevant doses it has been reported to only have marginal effects on the velocity of orthodontic tooth movement (OTM). Its effects on associated dental root resorptions, osteoclastogenesis, trabecular number in the alveolar bone and periodontal bone loss during OTM, however, have not yet been investigated. Material and methods: 40 male Fischer344 rats were divided into four groups: 1.5 ml tap water/day p.o. (control, 1), additional 7.8 mg/kg/day etoricoxib (normal dose) for three (2) or seven (3) days/week and 13.1 mg/kg/day (high dose) for seven days/week, respectively (4). After a week of premedication, OTM in anterior direction of the first left upper molar was performed for 28 days by means of a nickel-titanium coil spring (0.25 N). We quantified OTM-associated dental root resorptions, osteoclastogenesis, trabecular number and periodontal bone loss by histomorphometrical, histochemical and mu CT analyses of the disected tooth-bearing upper jaw sections. Results: After 28 days of OTM, associated reduction of trabecular number seemed to be slightly alleviated by high doses of etoricoxib, whereas no significant other etoricoxib effects in the doses administered could be detected regarding OTM-induced or -associated dental root resorptions, osteoclastogenesis or periodontal bone loss. Conclusions: Dental root resorptions, osteoclastogenesis and periodontal bone loss during OTM in rats were not significantly affected by etoricoxib in the clinically relevant dosages investigated with only a slight inhibitory effect on bone remodelling to be expected at high dosages. Etoricoxib is therefore not suitable for the prevention of these detrimental effects, but could be a suitable analgesic during OTM, as it has been reported not to affect tooth movement. (C) 2020 Elsevier GmbH. All rights reserved.
Metadata last modified: 11 Oct 2021 12:41